nach oben

Erschienen in:

01.05.2011

Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician

verfasst von: Tiago L. L. Leiria, Renato D. Lopes, Judson B. Williams, Jason N. Katz, Renato A. K. Kalil, John H. Alexander

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are approved for this indication. This paper reviews the main heart valve guidelines focusing on the use of oral anticoagulation in these patients.

Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 121:948–954PubMedCrossRef

Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607PubMedCrossRef

Prandoni A (1942) The anticoagulants heparin and the dicoumarin 3,3′-methylene-bis-(4-hydroxycoumarin). Bull N Y Acad Med 18:433–458PubMed

Oliva Berini E, Galan Alvarez P, Pacheco Onrubia AM (2008) Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin. Med Clin (Barc) 131:96–97CrossRef

Jensen CF, Christensen TD, Maegaard M, Hasenkam JM (2009) Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. J Thromb Thrombolysis 28:276–281PubMedCrossRef

Fihn SD, Gad isseur AA, Pasterkamp E et al (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 90:260–266PubMed

Leiria TL, Pellanda L, Miglioranza MH et al (2010) Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic. Arq Bras Cardiol 94:41–45PubMedCrossRef

Petersen P, Grind M, Adler J (2003) Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 41:1445–1451PubMedCrossRef

Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285–2293PubMedCrossRef

10.

Schwarz UI, Ritchie MD, Bradford Y et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008PubMedCrossRef

11.

Cadamuro J, Dieplinger B, Felder T et al (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66:253–260PubMedCrossRef

12.

Kakar P, Lane D, Lip GY (2006) Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. Chest 130:1296–1299PubMed

13.

Kuijer PM, Hutten BA, Prins MN, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457–460PubMedCrossRef

14.

Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428PubMedCrossRef

15.

Fang MC, Chang Y, Hylek EM et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745–752PubMed

16.

Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105:91–99PubMedCrossRef

17.

Cannegieter SC, Rosendaal FR, Briet E (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89:635–641PubMed

18.

Cannegieter SC, Rosendaal FR, Wintzen AR et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17PubMedCrossRef

19.

Dasi LP, Simon HA, Sucosky P, Yoganathan AP (2009) Fluid mechanics of artificial heart valves. Clin Exp Pharmacol Physiol 36:225–237PubMedCrossRef

20.

ElBardissi AW, DeBardino DJ, Chen FY, Yamashita MH, Cohn LH (2010) Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 139:1137–1145PubMedCrossRef

21.

Baudet EM, Puel V, McBride JT et al (1995) Long-term results of valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 109:858–870PubMedCrossRef

22.

Bjork VO, Henze A (1975) Management of thrombo-embolism after aortic valve replacement with the Bjork-Shiley tilting disc valve. Medicamental prevention with dicumarol in comparison with dipyridamole—acetylsalicylic acid. Surgical treatment of prosthetic thrombosis. Scand J Thorac Cardiovasc Surg 9:183–191PubMed

23.

Torn M, Cannegieter SC, Bollen WL et al (2009) Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 169:1203–1209PubMedCrossRef

24.

Acar J, Iung B, Boissel JP et al (1996) AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94:2107–2112PubMed

25.

Hering D, Piper C, Bergemann R et al (2005) Thromboembolic and bleeding complications following St. Jude medical valve replacement: results of the German experience with low-intensity anticoagulation study. Chest 127:53–59PubMedCrossRef

26.

Massel D, Little SH (2001) Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 37:569–578PubMedCrossRef

27.

Larson RJ, Fisher ES (2004) Should aspirin be continued in patients started on warfarin? J Gen Intern Med 19:879–886PubMedCrossRef

28.

Turpie AG, Gent M, Laupacis A et al (1993) A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 329:524–529PubMedCrossRef

29.

Little SH, Massel DR (2003) Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 4:CD003464PubMed

30.

Manzano-Fernandez S, Marin F, Pastor-Perez FJ et al (2008) Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 134:559–567PubMedCrossRef

31.

Rogacka R, Chieffo A, Michev I et al (2008) Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv 1:56–61PubMedCrossRef

32.

Salem DN, O’Gara PT, Madias C, Pauker SG (2008) Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th edn). Chest 133:593S–629SPubMedCrossRef

33.

Vahanian A, Baumgartner H, Bax J et al (2007) Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 28:230–268PubMed

34.

Triple Therapy in Patients on Oral Anticoagulation after Drug Eluting Stent Implantation (ISAR-TRIPLE). ClinicalTrials.gov Identifier: NCT00776633. Accessed 14 Jan 2011

35.

Schlitt A, Hauroeder B, Buerke M et al (2002) Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thromb Res 107:39–43PubMedCrossRef

36.

McKellar SH, Thompson JL III, Garcia-Rinaldi RF, Macdonald RJ, Sundt TM III, Schaff HV (2008) Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine. J Thorac Cardiovasc Surg 136:908–914PubMedCrossRef

37.

Butany J, Ahluwalia MS, Munroe C et al (2003) Mechanical heart valve prostheses: identification and evaluation. Cardiovasc Pathol 12:1–22PubMedCrossRef

38.

Gherli T, Colli A, Fragnito C et al (2004) Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 110:496–500PubMedCrossRef

39.

Colli A, Verhoye JP, Heijmen R et al (2008) Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION registry survey results. Eur J Cardiothorac Surg 33:531–536PubMedCrossRef

40.

Colli A, D’Amico R, Mestres CA et al (2010) Is early antithrombotic therapy necessary after tissue mitral valve replacement? J Heart Valve Dis 19:405–411PubMed

41.

Aramendi JI, Mestres CA, Martinez-Leon J, Campos V, Munoz G, Navas C (2005) Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 27:854–860PubMedCrossRef

42.

Kearon C, Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506–1511PubMedCrossRef

43.

Bonow RO, Carabello BA, Chatterjee K et al (2008) 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118:e523–e661PubMedCrossRef

44.

Bonow RO, Carabello BA, Kanu C et al (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114:e84–e231PubMedCrossRef

45.

Garcia DA, Regan S, Henault LE et al (2008) Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 168:63–69PubMedCrossRef

46.

Wijdicks EF, Schievink WI, Brown RD, Mullany CJ et al (1998) The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 42:769–773PubMedCrossRef

47.

Babikian VL, Kase CS, Pessin MS, Caplan LR, Gorelick PB (1988) Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves. Stroke 19:407–408PubMed

48.

Roudaut R, Lafitte S, Roudeaut MF et al (2009) Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis 102:269–277PubMedCrossRef

49.

Gupta D, Kothari SS, Bahl VK et al (2000) Thrombolytic therapy for prosthetic valve thrombosis: short- and long-term results. Am Heart J 140:906–916PubMedCrossRef

50.

Caceres-Loriga FM, Perez-Lopez H, Morlans-Hernandez K et al (2006) Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis 21:185–190PubMedCrossRef

51.

Karthikeyan G, Math RS, Mathew N et al (2009) Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation 120:1108–1114PubMedCrossRef

52.

Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef

53.

Kulik A, Le May M, Wells GA, Mesana TG, Ruel M (2005) The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Curr Control Trials Cardiovasc Med 6:15PubMedCrossRef

54.

CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRef

55.

Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374:565–576PubMedCrossRef

Titel: Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician
verfasst von: Tiago L. L. Leiria
Renato D. Lopes
Judson B. Williams
Jason N. Katz
Renato A. K. Kalil
John H. Alexander
Publikationsdatum: 01.05.2011
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2011
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-011-0574-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Highlights of the sixth annual Platelet Colloquium

Fibrinogenolytic and anticoagulant activities in the tissue covering the stingers of marine stingrays Dasyatis sephen and Aetobatis narinari

High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population

Acquired factor V inhibitors: a systematic review

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor